Vaccinex Stock Today
| VCNX Stock | USD 3.62 0.02 0.56% |
Performance0 of 100
| Odds Of DistressLess than 50
|
Vaccinex is trading at 3.62 as of the 24th of November 2024; that is 0.56 percent increase since the beginning of the trading day. The stock's open price was 3.6. Vaccinex has 50 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Vaccinex are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of October 2024 and ending today, the 24th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of August 2018 | Category Healthcare | Classification Health Care |
Vaccinex, Inc., a clinical-stage biotechnology company, focuses on treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D . Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York. Vaccinex operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 2.68 M outstanding shares of which 127.5 K shares are at this time shorted by private and institutional investors with about 0.74 trading days to cover. More on Vaccinex
Moving together with Vaccinex Stock
Moving against Vaccinex Stock
Follow Valuation Profit Patterns Daily Balance Of Power
Check how we calculate scores
Vaccinex Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVaccinex can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vaccinex's financial leverage. It provides some insight into what part of Vaccinex's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Vaccinex (VCNX) is traded on NASDAQ Exchange in USA. It is located in 1895 Mount Hope Avenue, Rochester, NY, United States, 14620 and employs 37 people. Vaccinex is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.69 M. Vaccinex conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.68 M outstanding shares of which 127.5 K shares are at this time shorted by private and institutional investors with about 0.74 trading days to cover.
Vaccinex currently holds about 11.4 M in cash with (17.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27.
Check Vaccinex Probability Of Bankruptcy
Ownership Allocation30% of Vaccinex outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change.
Check Vaccinex Ownership Details
Vaccinex Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2024-06-30 | 0.0 | |
| Tacita Capital Inc. | 2024-06-30 | 0.0 | |
| Point72 Asset Management, L.p. | 2024-09-30 | 166 K | |
| Armistice Capital, Llc | 2024-09-30 | 164 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.2 K | |
| Tower Research Capital Llc | 2024-06-30 | 1.3 K | |
| Group One Trading, Lp | 2024-06-30 | 67.0 | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 53.0 | |
| Royal Bank Of Canada | 2024-06-30 | 39.0 | |
| Bank Of America Corp | 2024-06-30 | 8.0 | |
| Capital Advisors, Ltd. Llc | 2024-09-30 | 3.0 |
Vaccinex Historical Income Statement
Vaccinex Stock Against Markets
Vaccinex Corporate Management
| Jill CPA | Chief Officer | Profile | |
| Jill Sanchez | Interim Controller | Profile | |
| MBA CFA | Chief Officer | Profile | |
| Ernest Smith | Senior Officer | Profile | |
| Maurice Zauderer | CEO, CoFounder | Profile | |
| Elizabeth Evans | COO Medicine | Profile | |
| John Leonard | Senior Development | Profile |
Additional Tools for Vaccinex Stock Analysis
When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.